Literature DB >> 9591573

Technetium-99m-HMPAO brain SPECT in Sjögren's syndrome.

C H Kao1, J L Lan, S P ChangLai, P U Chieng.   

Abstract

UNLABELLED: Technetium-99m-hexamethylpropylene amine oxime (HMPAO) brain images with fanbeam SPECT, in combination with surface three-dimensional display, were used to detect basal ganglion and cerebral cortex anomalies in Sjögren's syndrome patients.
METHODS: Forty-eight female Sjögren's syndrome patients with normal brain CT or magnetic resonance imaging findings were enrolled in this study and were investigated using 99mTc-HMPAO brain images with fanbeam SPECT and surface three-dimensional display. These patients were separated into two subgroups. Group 1 consisted of 38 patients with definite neuropsychiatric symptoms/signs and Group 2 consisted of 10 patients without any neuropsychiatric symptoms/signs.
RESULTS: Fanbeam SPECT demonstrated unilateral or bilateral hypoactivity of basal ganglia and thalamus in 14% and 0% of patients in Groups 1 and 2, respectively. Using surface three-dimensional display of the brain, local hypoactivity anomalies were found in the brain cortex of 53% and 20% of patients in Groups 1 and 2, respectively. In Group 1 patients, parietal lobes were the most common areas of brain involvement. The cerebellum and thalamus were the least common areas of brain involvement. In Group 2 patients, parietal and temporal lobes were the most common areas of brain involvement.
CONCLUSION: This study suggests that 99mTc-HMPAO brain imaging with fanbeam SPECT, in combination with surface three-dimensional display, is a sensitive tool for detecting regional cerebral anomalies in Sjögren's syndrome patients with and without neuropsychiatric symptoms/signs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9591573

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  6 in total

Review 1.  CNS involvement in primary Sjögren's syndrome: prevalence, clinical aspects, diagnostic assessment and therapeutic approach.

Authors:  M Govoni; M Padovan; N Rizzo; F Trotta
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement-a preliminary report.

Authors:  S S Sun; F Y Liu; J J P Tsai; R F Yen; C H Kao; W S Huang
Journal:  Rheumatol Int       Date:  2003-04-09       Impact factor: 2.631

3.  Central nervous system involvement in Sjogren's syndrome.

Authors:  F C Soliotis; C P Mavragani; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

4.  Silent central nervous system involvement in Egyptian Behçet's disease patients: clinical, psychiatric, and neuroimaging evaluation.

Authors:  Hania Zayed; Dina Effat; Zeinab Nawito; Amany Ahmed Abdou; Mohamed Nasr El Din; Sherif El-Refaei; Mahasen Amin; Yasser Mohamed; Amr Amin; Ahmed Wafie; Khaled Abu El-Einin
Journal:  Clin Rheumatol       Date:  2011-03-08       Impact factor: 2.980

5.  Abnormal regional cerebral blood flow on 99mTc ECD brain SPECT in patients with primary Sjögren's syndrome and normal findings on brain magnetic resonance imaging.

Authors:  C P Chang; Y C Shiau; J J Wang; S T Ho; A Kao
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

6.  Detecting abnormal regional cerebral blood flow in patients with primary Sjögren's syndrome by technetium-99m ethyl cysteinate dimer single photon emission computed tomography of the brain--a preliminary report.

Authors:  W S Huang; P Y Chiu; A Kao; C H Tsai; C C Lee
Journal:  Rheumatol Int       Date:  2003-02-18       Impact factor: 2.631

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.